Vensica Medical Raises $11M to Advance Needle-Free Overactive Bladder Treatment
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from Merz and Laborie, to advance a minimally invasive OAB treatment option. • Vensica's technology delivers Xeomin® directly to the bladder wall, potentially offering a more comfortable alternative to traditional injections for OAB patients. • The strategic partnership with Merz grants Vensica exclusive rights to use Xeomin® in needle-free applications for urologic indications, enhancing its clinical development.
Vensica Medical Raises $11M to Advance Needle-Free OAB Treatment
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie, to advance minimally invasive OAB treatment. • Vensica's technology delivers Xeomin® directly to the bladder wall, offering a potentially more comfortable alternative to traditional injections for OAB patients. • The collaboration with Merz grants Vensica exclusive rights to use Xeomin® in needle-free applications for urologic indications, enhancing its next-generation urology treatments.
Vensica Medical Raises $11M to Advance Needle-Free Overactive Bladder Treatment
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from Merz and Laborie, to advance minimally invasive OAB treatment. • Vensica's technology delivers Xeomin® directly to the bladder wall, offering a potentially more comfortable alternative to traditional injections. • The strategic partnership with Merz grants Vensica exclusive rights to Xeomin® for needle-less urologic applications, enhancing next-generation urology treatments.